Patents Assigned to AbbVie Biotherapeutics Inc.
  • ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20230321271
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: February 22, 2023
    Publication date: October 12, 2023
    Applicants: AbbVie Biotherapeutics Inc., AbbVie Inc.
    Inventors: Christian B. Allan, Louie Naumovski, Edward B. Reilly
  • Anti-huLRRC15 antibody drug conjugates and methods for their use
    Patent number: 11045480
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: June 29, 2021
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
  • Anti-4-1BB antibodies and their uses
    Patent number: 10875921
    Abstract: The present disclosure provides novel anti-4-1BB antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 29, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko Akamatsu, Jieyi Wang
  • Anti-CD40 antibody
    Patent number: 10844131
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: November 24, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Anti-PD-1 antibodies and their uses
    Patent number: 10730953
    Abstract: The present disclosure provides novel anti-PD-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 4, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Daniel E. H. Afar, Fiona A. Harding, Josue Samayoa
  • Anti-OX40 antibodies and their uses
    Patent number: 10604584
    Abstract: The present disclosure provides novel anti-OX40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: March 31, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventor: Fiona A. Harding
  • Anti-cMet antibody drug conjugates and methods for their use
    Patent number: 10603389
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: March 31, 2020
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Christian B. Allan, Louie Naumovski, Edward B. Reilly
  • Anti-CD40 antibodies
    Patent number: 10597460
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: March 24, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Anti-OX40 antibodies and their uses
    Patent number: 10556962
    Abstract: The present disclosure provides novel anti-OX40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: February 11, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventor: Fiona A. Harding
  • Anti-CD40 antibodies
    Patent number: 10519243
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 31, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 10442859
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: October 15, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Nucleic acid molecules encoding anti-CD40 antibodies
    Patent number: 10400041
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: September 3, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Anti-cMet antibody drug conjugates and methods for their use
    Patent number: 10383948
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: August 20, 2019
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Christian B. Allan, Mark Anderson, Louie Naumovski, Edward B. Reilly, Jieyi Wang
  • ANTI-4-1BB ANTIBODIES AND THEIR USES
    Publication number: 20190194329
    Abstract: The present disclosure provides novel anti-4-1BB antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Application
    Filed: May 26, 2017
    Publication date: June 27, 2019
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko AKAMATSU, Jieyi WANG
  • Anti-CS1 antibodies and antibody drug conjugates
    Patent number: 10308713
    Abstract: The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: June 4, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Han K. Kim, Louie Naumovski
  • Bispecific binding proteins that bind CD40 and mesothelin
    Patent number: 10233258
    Abstract: The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: March 19, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko Akamatsu, Patricia Culp, Charles M. Forsyth, Ping Y. Huang, David Powers, Alan F. Wahl, Shiming Ye
  • Anti-huLRRC15 antibody drug conjugates and methods for their use
    Patent number: 10195209
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 5, 2019
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
  • Anti-huLRRC15 antibody drug conjugates and methods for their use
    Patent number: 10188660
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: January 29, 2019
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
  • Fc variants with improved complement activation
    Patent number: 10150814
    Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with improved potency and efficacy in activation of complement-dependent cytotoxicity.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 11, 2018
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Paul R. Hinton, Veronica Juan
  • Anti-OX40 antibodies and their uses
    Patent number: 10040864
    Abstract: The present disclosure provides novel anti-OX40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 7, 2018
    Assignee: AbbVie Biotherapeutics Inc.
    Inventor: Fiona A. Harding